Effect of Inotropes in Patients with Advanced Heart Failure: A Meta-Analysis of Randomized Trials

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Advanced heart failure (AHF) presents significant morbidity and mortality challenges.
• Inotropic agents (dobutamine, levosimendan, milrinone) are used to enhance cardiac output but their mortality impact is debated.
• Limited head-to-head comparisons hinder definitive conclusions on inotrope effectiveness in AHF.

Purpose of the Study:

• To systematically compare the efficacy of inotropes against placebo or each other in reducing mortality among AHF patients.
• To synthesize evidence from randomized controlled trials (RCTs) on inotropic therapy in advanced heart failure.
• To investigate potential moderators of inotrope effects on mortality in AHF.

Main Methods:

• A systematic review and meta-analysis adhering to PRISMA guidelines, registered with PROSPERO.
• Comprehensive literature search across multiple databases (Scopus, CENTRAL, Google Scholar, PubMed) for RCTs from 2000 onwards.
• Random-effects model used to calculate risk differences (RD) for mortality, with heterogeneity assessed using Cochrane Q, Tau², and I² statistics.

Main Results:

• Twenty-four RCTs with 2,862 participants were analyzed.
• The pooled risk difference for mortality was -0.023 (95% CI: -0.046 to 0.000; p=0.055), showing no statistically significant difference.
• Subgroup analyses and meta-regression did not resolve heterogeneity; funnel plot indicated potential publication bias.

Conclusions:

• Inotropic agents demonstrated a non-significant trend towards reduced mortality in advanced heart failure patients.
• Significant heterogeneity among studies limits definitive conclusions regarding the overall benefit of inotropes.
• Larger, well-designed RCTs are essential to identify specific patient subgroups that may benefit from inotropic therapy.